


## Notable LOEs through 2028

| 2023                                                                                                          |                     | 2024                                                                                                  |                     | 2025                                                                                                          |                       | 2026                                                                                                                                              |                          | 2027                                                                                              |                     | 2028                                                                                                            |                     |
|---------------------------------------------------------------------------------------------------------------|---------------------|-------------------------------------------------------------------------------------------------------|---------------------|---------------------------------------------------------------------------------------------------------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|---------------------------------------------------------------------------------------------------|---------------------|-----------------------------------------------------------------------------------------------------------------|---------------------|
| Company                                                                                                       | Product ('22 Sales) | Company                                                                                               | Product ('23 Sales) | Company                                                                                                       | Product ('24 Sales)   | Company                                                                                                                                           | Product ('25 Sales)      | Company                                                                                           | Product ('26 Sales) | Company                                                                                                         | Product ('27 Sales) |
|  <b>abbvie</b>                | Humira (\$21B)      |  <b>REGENERON</b>    | Eylea (\$10B)       |  <b>AstraZeneca</b>          | Soliris (\$2.7B)      |  <b>NOVARTIS</b>                                               | Entresto (\$7B)          |  <b>Pfizer</b> | Eliquis (\$15B)     |  <b>MERCK</b>                | Keytruda (\$30B)    |
|  <b>Johnson &amp; Johnson</b> | Stelara (\$10B)     |  <b>AstraZeneca</b>  | Brilinta (\$1.4B)   |  <b>Bristol Myers Squibb</b> | Yervoy (\$3B)         |  <b>EXELIXIS</b><br><small>Innovation for patient care</small> | Cabometyx (\$1B)         |  <b>abbvie</b> | Imbruvica (\$12B)   |  <b>Bristol Myers Squibb</b> | Opdivo (\$13B)      |
|  <b>Jazz Pharmaceuticals</b>  | Xyrem (\$1B)        |  <b>Jazz</b>         | Xarelto (\$3B)      |  <b>Pfizer</b>               | Xeljanz (\$2B)        |  <b>Bristol Myers Squibb</b>                                   | Pomalyst (\$2.5B)        |  <b>Pfizer</b> | Ibrance (\$9B)      |  <b>AMGEN</b>                | Otezla (\$3B)       |
|  <b>Biogen</b>                | Tysabri (\$1.9B)    |  <b>novo nordisk</b> | Victoza (\$1.3B)    |  <b>AMGEN</b>                | Prolia / Xjeva (\$6B) |  <b>MERCK</b>                                                  | Januvia / Janumet (\$1B) |  <b>Lilly</b>  | Trulicity (\$8B)    |  <b>GSK</b>                  | Tivicay (\$4.5B)    |
|  <b>sunovion</b>              | Latuda (\$2B)       |                                                                                                       |                     |                                                                                                               |                       |  <b>Roche</b>                                                  | Perjeta (\$5.5B)         |                                                                                                   |                     |                                                                                                                 |                     |
|  <b>NOVARTIS</b>              | Gilenya (\$1.6B)    |                                                                                                       |                     |                                                                                                               |                       |                                                                                                                                                   |                          |                                                                                                   |                     |                                                                                                                 |                     |
|  <b>Takeda</b>              | Vyvanse (\$3.4B)    |                                                                                                       |                     |                                                                                                               |                       |                                                                                                                                                   |                          |                                                                                                   |                     |                                                                                                                 |                     |
| <b>Total 'At-Risk' Revenue:</b>                                                                               |                     | <b>~\$41B</b>                                                                                         |                     | <b>~\$16B</b>                                                                                                 |                       | <b>~\$14B</b>                                                                                                                                     |                          | <b>~\$17B</b>                                                                                     |                     | <b>~\$44B</b>                                                                                                   |                     |